Stay updated with breaking news from Vanessa malier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kurma Partners announced the first closing of its Growth Opportunities fund at €160 million. Meeting the demand of the growing maturity of the European biotech and healthtech ecosystem, this new fund ....
(2) COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win technology, announced today that it has raised EUR 127 million in Series B financing. The financing round was led by HBM Healthcare Investments, and other new investors joining the round included Vivo Capital, Kurma Partners, Avoro Capital, RA Capital Management, Samsara Biocapital, Idinvest Partners 1, PFM Health Sciences, Soleus Capital, Eir Ventures and Serrado Capital, with the participation of existing investors Novo Seeds, Lundbeckfonden Emerge and Sunstone Life Science Ventures. Additionally, Dr. Priyanka Belawat of HBM Partners, Jack B. Nielsen of Vivo Capital and Vanessa Malier of Kurma Partners will join IO Biotech s board of directors as part of the closing of the financing. ....